Introduction: The incidence and predictors of tricuspid regurgitation (TR) after permanent pacemaker (PM) implantations have not been well evaluated. We attempted to determine TR's natural course and predictors, especially focusing on the influence of atrial fibrillation (AF).
INTRODUCTION
Patients with endocardial pacing leads are at an ongoing risk of tricuspid valve (TV) damage or dysfunction, which could progress to tricuspid regurgitation (TR). 1 The development of TR has been associated with long-term morbidities and mortality. [2] [3] [4] [5] [6] Prior studies have determined the incidence of TR after a pacemaker (PM) implantation is 7-39%. [7] [8] [9] [10] [11] [12] This is expected to escalate as the number of devices increases in line with a greater proportion of older people in the overall population. However, despite its growing clinical significance, large clinical data focused on the chronological aspect of TR development with sufficient patient numbers and follow-up information are not available.
Regarding the attributable factors of TR progression, primary factors, such as lead-related valvular injury, 1, 8, 13 and secondary factors, such as enlargement of the right atrium (RA) or right ventricle (RV), 5, 9, 14 concomitant left-sided heart disease, 5 and atrial fibrillation (AF), 14 have been reported. AF was recently highlighted as an important attributable factor leading to isolated TR progression without coincident structural abnormalities. 15, 16 The unique clinical importance of AF in patients with PM-related TR progression is that this could be a potential "modifiable" factor due to recent remarkable evolutions in the rhythm control methods. Therefore, in the current study, we attempted to determine the incidence and predictors of moderate to severe TR after PM implantations by analyzing the follow-up data in our PM registry. We hypothesized that the burden of AF was associated with the development of TR. 
METHODS

Study population
We initially screened 907 patients who received a de novo PM implan- 
Data collection and follow-up
The patients' demographic, electrocardiographic, echocardiographic, and outcome data were obtained by careful review of the medical records by independent research personnel. The comorbidity status and baseline work-up data were gathered at the time of the admission for the PM implantation. The baseline echocardiographic data, such as the cardiac chamber dimensions and left ventricular ejection fraction, were measured according to the current guideline recommendations. 17 Follow-up echocardiography was encouraged every 1-2 years for all patients, but the decision was made by the attending physician based on the patient's clinical status. AF was diagnosed upon documentation in any form of electrocardiography, such as the 12-lead electrocardiogram (ECG), Holter monitoring, in-hospital telemetry monitoring, or electrograms recorded by the PM. 18 The diagnosis of persistent or permanent AF (PeAF) was defined as documented AF on two consecutive ECGs at least 7 days apart. [19] [20] [21] [22] The diagnosis of any form of AF was only made when it was documented before the occurrence of our main study outcomes. The distinction between persistent and permanent AF was not considered because the decision regarding rhythm control in PeAF was usually driven by the attending physician. The patients whose PAF progressed to PeAF during follow-up were assigned to the PeAF group. Sinus node disease (SND) was diagnosed in symptomatic patients with documented ECGs with sinus pauses, block, or tachycardia-bradycardia syndrome. During the procedure, in principle, the atrial lead was placed in the right atrial appendage, and ventricular lead at the right ventricular apex.
The study subjects were usually followed-up within 3 months postindex procedure at an outpatient visit and yearly thereafter. Interrogation data regarding the lead status and PM settings were gathered on the day after the index procedure. The cumulative percentage of atrial and ventricular pacing was measured during the initial follow-up at the outpatient visit. Follow-up data were gathered by a detailed review of the medical records or direct telephone interviews with the patients or their closest guardian. The median follow-up duration of the study population was 7.6 years (interquartile range [IQR]: 4.9-10.7 years).
Study outcome and definition
The main outcome of the current study was the incidence of moderate to severe TR. This diagnosis was made by a comprehensive twodimensional and Doppler echocardiographic evaluation and most frequently depended on a combination of quantitative parameters, such as a jet area >5 cm 2 , vena contracta width >0.7 cm, and proximal isovelocity surface area radius >5 mm. 23 TR severity was assessed by an independent imaging specialist who was blinded to the clinical outcomes. The first diagnosed episode of moderate to severe TR throughout the study period was defined as the primary outcome regardeless of any subsequent changes. Another main study outcome was isolated TR, which was defined as a moderate to severe TR diagnosis without any evidence of structural heart disease (SHD) that could induce or worsen the secondary TR. 15 
Statistical analysis
The summary statistics are presented as the mean ± standard deviation or median with IQRs for continuous variables and as numbers and percentages for categorical variables. For comparisons of continuous variables, an unpaired Student's t-test or Mann-Whitney U test was used. Categorical variables were compared using the 2 
test or
Fisher's exact test, as appropriate. A Cox proportional-hazard model was employed to identify the independent predictors of future significant TR. Variables with a P-value of ≤ 0.1 and those with significant clinical relevance were included in the multivariable Cox model. The final models for predicting each study outcome were determined using backward elimination procedures where the least significant variable was eliminated one by one from the initial model. The proportional hazard assumption was tested by examination of the log (−log[survival]) curves and partial (Schoenfeld) residuals. The presence of paroxysmal AF (PAF) or PeAF was regarded as a time-dependent covariate, and therefore an extended Cox proportional model was used for the final model. The cumulative incidence of the study outcomes was generated using the Kaplan-Meier method and compared using the log-rank test.
All P-values were two-sided and a P-value of <0.05 was considered significant. In situations with multiple comparisons, Bonferroni's correction was applied. All statistical analyses were performed using the R 3.1.2 software (http://cran.r-project.org/).
RESULTS
Patient characteristics
From 2001 to 2012, a total 907 patients received PMs at our center, of who 530 met our inclusion and exclusion criteria. The mean patient age was 63.4 ± 11.5 years, and 48.8% of subjects were male. The primary indication for the PM was SND and atrioventricular block in 44.2% and 55.8% patients, respectively. The mean number of echocardiographic examinations following the PM implantation was 3.5 ± 2.8 times. Moderate to severe TR developed in 77 (14.5%) patients during the followup period (Table 1 ). Approximately half of those patients were documented with isolated TR (n = 37, 48.1%), and concomitant SHD was observed in 51.9% (n = 40). The diagnosis of SHD included patients with congestive heart failure (CHF, n = 28), moderate to severe valvular heart disease (n = 31, 12 combined with CHF), and constrictive pericarditis (n = 1). Symptoms attributable to the moderate to severe TR were found in 40.3% (31/77) of patients, and were numerically higher in those with SHD compared to isolated TR (50% vs 29.7%).
The characteristics of the patients with and without moderate to severe TR are summarized in Table 1 . The mean age and proportion of male patients did not significantly differ between the patients with and without moderate to severe TR. A previous history of diabetes mellitus (DM), peripheral artery disease (PAD), CHF, coronary artery disease (CAD), and prior open-heart surgery were significantly more frequent in the patients with TR. The mean CHA 2 DS 2 -VASc score was significantly higher in the patients that developed moderate to severe TR. Regarding the electrocardiography data (Table 2) , the frequency of preexisting PeAF (7.8% vs 2.9%, P = 0.069) and newly developed PeAF (20.8% vs 7.1%, P < 0.001) was higher in the patients who developed moderate to severe TR than those without progression of the TR. Notably, 71.6% (48/67) of the PeAF patients were not diagnosed during the baseline evaluation, but were during the follow-up. The frequency of PAF did not significantly differ between the two groups.
The baseline echocardiography data revealed that the left atrial (LA)
anterior-posterior diameter and left ventricular end-diastolic dimensions (LVEDD) were significantly larger in patients who developed TR. Furthermore, the prevalence of preexisting mild TR and moderate to severe mitral regurgitation (MR) were significantly higher in the patients who developed TR.
We also compared the characteristics of the patients who developed isolated TR to the control population. The proportion of patients with preexisting PeAF (10.8% vs 2.9%, P = 0.038) and newly developed PeAF (29.7% vs 7.1%, P < 0.001) was higher in the patients with isolated TR.
Predictors of TR after PM implantations
The association between each clinical variable and the development of TR was assessed by the Cox proportional hazard model (Table 3 ). In the univariate analysis, a previous history of DM, CHF, CAD, PAD, chronic obstructive pulmonary disease (COPD), and chronic renal failure; preexisting mild TR; moderate to severe AR and MR; the RA-RV pressure gradient (PG); PeAF; CHA 2 DS 2 -VASc score; LVEDD; and LA diameter were associated with a future progression of TR. The univariate predictors of isolated TR were a history of a prior stroke or transient ischemic attack, DM, CHA 2 DS 2 -VASc score, preexisting mild TR, PAF, and PeAF.
To identify the independent predictors of future moderate to severe TR and an isolated TR progression, we established two multivari- 
Clinical implication of AF on the progression of TR
The chronological relationship between the diagnosis of PeAF and progression of TR is plotted in Supplementary Figure S1 . A diagnosis of PeAF preceded the progression of TR in 70.9% (22/31) of the patients who had both diagnosed throughout the study period. The median time from PeAF to the progression of TR was 13 months (IQR: 6-77 months). Since PeAF was identified as a common independent predictor of moderate to severe TR and isolated TR progression in both final models, we further analyzed the data by stratifying the patients into three groups according to their type of AF (Figure 2 ). In the Note: CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; OHS = open heart surgery; PAD = peripheral artery disease; TIA = transient ischemic accident; TR = tricuspid regurgitation. Kaplan-Meier analysis, the incidence of overall TR at the 8-year followup was 21.8% ± 5.7%, 12.9% ± 3.1%, and 11.6% ± 2.3% for the patients with PeAF, with PAF, and without AF, respectively (overall log-rank: P = 0.002). In the pairwise comparison, the rate of moderate to severe TR in the PeAF group was significantly higher than that in those with PAF or without AF (P < 0.001 for both groups), but a comparison of the incidence between the PAF group and group without AF was not significant (P = 0.301). The incidence of isolated TR exhibited a similar trend (18.6% ± 5.7%, 6.6% ± 2.0%, 4.2% ± 1.7% for the PeAF, PAF, and without AF groups, respectively; overall P < 0.001). Again, the incidence of isolated TR was significantly higher in the patients with PeAF than in those with PAF (P = 0.007) or without AF (P < 0.001), but was not statistically significant between the PAF group and group without AF (P = 0.150). In the subanalysis, there was a statistically nonsignificant trend toward a higher rate of overall and isolated TR progression in those with preexisting PeAF than those with incidental PeAF (32.9 ± 12.6% vs 17.4 ± 6.0%, P = 0.150 for overall TR progression; 21.9 ± 15.4% vs 16.9 ± 6.4%, P = 0.437 for isolated TR progression; Supplementary Figure S2 ).
DISCUSSION
In this retrospective review of our PM registry, we discovered several important findings regarding moderate to severe TR after PM implantations: (1) The incidence of moderate to severe TR after a PM implantation was 14.5% during 7 years of follow-up. (2) Approximately half of the TR cases were associated with left-sided heart disease, and the remainder manifested with an isolated form. (3) The predictors of moderate to severe TR and isolated TR differed. (4) PeAF was a common significant predictor of both moderate to severe TR and isolated TR progression, and its association was more robust for isolated TR. forations, and impingement. These mechanical factors were reproduced in the subsequent series. 8, 11 More recent studies have identified the predictors that are not directly related to PM leads, such as the age, an enlarged RA or RV, the RV systolic pressure, and mitral valve surgery. 5, 7, 9 However, most prior studies had the common limitation of a cross-sectional design and insufficient patient numbers and failed to determine the "modifiable" factors. In this regard, the most compelling strength of our study was the longitudinal patient follow-up over 7 years. As depicted in Figure 2 Because PeAF was a common and potentially modifiable predictor of the progression of overall moderate to severe TR as well as isolated TR, we investigated this further. In our data, PeAF was independently associated with moderate to severe TR and its influence was more robust for isolated TR, whereas PAF was not. Furthermore, the presence of DM, which was another common predictor of TR, has already been linked to atrial remodeling and the progression of AF. 24 Therefore, we supposed that the burden of AF, in other words, progression of PAF to PeAF, has a fundamental risk of the progression of TR. 25 The association between AF and TR has already been well described in the study by Najib et al. 26 In their sound paper, PeAF patients exhibited characteristics of a larger RA and RV area, and a longer tricuspid annular (TA) diameter. They explained their findings by a mechanism of RA and TA dilatation after long-standing AF, which would ultimately lead to TV systolic coaptation failure and severe TR. Their next analysis of a PM subgroup also demonstrated the same results. 14 The association between AF and annular dilatation has already been well recognized for the mitral annulus. [27] [28] [29] Zhou et al. 30 suggested even more vulnerability of the RA than the LA for chamber dilatation and significant regurgitation in patients with lone AF. The association between chronic AF, annular dilatation, and isolated TR was demonstrated in three-dimensional echocardiography. 16 We, therefore, believe AF would contribute to the progression of both primary and secondary TR through the common mechanism of RA or TA dilatation. This finding was clinically important because AF could be a potentially "modifiable" attributing factor for PM-related TR. The report of a decreased TR extent after a maze operation would support our concept. 31 The role of rhythm control for the prevention of PM-related TR should be assessed in future prospective studies.
TA B L E 2 Electrocardiography, echocardiography, and pacemaker data of the patients
TA B L E 3 Predictors of the progression of tricuspid regurgitation
There were several limitations to our current study. The inherent limitation of selection bias that stems from a retrospective cohort design was inevitable. There was the possibility of a misclassification of PAF to PeAF with our definition of PeAF based on the consecutive ECG findings. On the contrary, the diagnosis of subclinical PeAF could be underestimated as it was only diagnosed when it was objectively documented on the electrocardiogram. The diagnosis of TR or related signs/symptoms could be underestimated because the prescription of echocardiography was largely made at the attending physician's discretion. Likewise, a PeAF diagnosis could also be underestimated. Although the long follow-up duration was a major strength of the current study, some recently identified echocardiographic parameters, such as the RA or RV size, RV function, or LV diastolic function on echocardiography, were not available. For the same reason, a detailed evaluation of any PM lead-associated TV damage was not fully considered in the current study. Moreover, the numbers of and intervals between echocardiographic examinations varied among the study patients because of the retrospective nature. Therefore, the chronological structural and functional changes in the heart chambers as well as valves could not be completely evaluated in this retrospective series and should be further evaluated in a larger prospective study.
CONCLUSION
In conclusion, patients with PM implantations are at an ongoing risk of moderate to severe TR. Continuous monitoring of the development of PeAF seemed to be important for preventing the progression of TR. The preventive role of a rhythm control strategy in these patients should be evaluated in future prospective or randomized studies.
